Yüklüyor......
Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma
BACKGROUND: Immunotherapy can take advantage of the immunogenic response that chemotherapy elicits in tumors. Gemcitabine is a standard agent used in the treatment of pancreatic cancer, with known effects on the tumor immune microenvironment. The combination immunotherapy of the GVAX cancer vaccine,...
Kaydedildi:
| Yayımlandı: | Ann Pancreat Cancer |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7220030/ https://ncbi.nlm.nih.gov/pubmed/32405624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2019.11.01 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|